Aqueous composition
By containing the aqueous composition containing a buffer and a chelating agent in the resin container, the problem of impurities dissolution in the aqueous composition is solved, and the storage effect is significantly improved by adding disodium ethylenediaminetetraacetate, ensuring 4-benzyl The stability of sodium ate and the long-term effectiveness of the composition.
Patent Information
- Application Number
- CN202380029644.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-25
- Filing Date
- 2023-03-24
- Publication Date
- 2024-11-15
AI Technical Summary
When the aqueous composition containing sodium 4-phenylbutyrate is contained in a resin container, impurities are easily dissolution from the container, and the prior art lacks an effective solution for storage effectiveness.
The aqueous composition is contained in a container formed of a resin containing a polyolefin, and the addition of a buffering agent and a chelating agent, especially disodium ethylenediaminetetraacetate, to the composition, to inhibit the dissolution of impurities and improve the storage effectiveness.
It effectively inhibits the dissolution of impurities in the resin container, and significantly improves the storage effectiveness of the aqueous composition, ensuring the stability of sodium 4-phenylbutyrate and the long-term effectiveness of the composition.
Smart Images

Figure BDA0005055225080000031 
Figure BDA0005055225080000121 
Figure BDA0005055225080000122
Abstract
Description
Technical Field
[0001] The first present invention and the second present invention will be described below in sequence.
[0002] The first present invention relates to an aqueous composition. Background Art
[0003] It is known that sodium 4-phenylbutyrate is metabolized to phenylacetic acid in the body and excreted into urine by combining with glutamic acid, and is used as a therapeutic drug for urea cycle disorders (Non-patent Document 1). Recently, it has been reported that sodium 4-phenylbutyrate is useful in preventing or treating eye diseases such as myopia or presbyopia (e.g., Patent Documents 1 and 2).
[0004] Prior art literature
[0005] Patent Literature
[0006] Patent Document 1: International Publication No. 2018 / 164113
[0007] Patent Document 2: International Publication No. 2020 / 129965
[0008] Non-patent literature
[0009] Non-patent document 1: Buphenyl (registered trademark) tablets 500 mg Buphenyl (registered trademark) granules 94% attachment Summary of the invention
[0010] Problems to be solved by the invention
[0011] Therapeutic drugs for urea cycle disorders with sodium 4-phenylbutyrate as an active ingredient are commercially available in the form of tablets and granules suitable for oral administration. On the other hand, there is no report on the behavior of aqueous compositions such as eye drops containing sodium 4-phenylbutyrate when they are contained in a resin container. The inventors of the present application have discovered that there is a new problem that when an aqueous composition containing sodium 4-phenylbutyrate is contained in a specific resin container, the dissolution of impurities from the resin container is promoted. The first object of the present invention is to provide a new aqueous composition, which is an aqueous composition containing 4-phenylbutyric acid or a derivative thereof contained in a resin container, and can inhibit the dissolution of impurities from the resin container.
[0012] Means for solving problems
[0013] The inventors of the present application have conducted intensive studies to solve the above problems and have found that elution of impurities from the resin can be suppressed by placing an aqueous composition containing sodium 4-phenylbutyrate in a container formed of a resin containing a polyolefin. The first present invention is based on this finding and provides the following inventions. [1]
[0015] An aqueous composition comprising (A) 4-phenylbutyric acid or an ester thereof or a pharmacologically acceptable salt thereof, wherein the aqueous composition is contained in a container in which a part or the whole of the part in contact with the aqueous composition is formed of a resin containing a polyolefin. [2]
[0017] The aqueous composition according to [1] further comprises (B) a buffer. [3]
[0019] The aqueous composition according to [1] or [2], further comprising (C) a chelating agent. [4]
[0021] The aqueous composition according to any one of [1] to [3], wherein the pH is 6.0 or more and 9.0 or less.
[0022] Effects of the Invention
[0023] According to the first present invention, there can be provided an aqueous composition containing 4-phenylbutyric acid or a derivative thereof contained in a resin container, wherein elution of impurities from the resin container is suppressed. DETAILED DESCRIPTION
[0024] Hereinafter, specific embodiments of the first present invention will be described in detail. However, the first present invention is not limited to the following embodiments.
[0025] The aqueous composition according to the present embodiment contains (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof (also referred to as "component (A)").
[0026] [(A) ingredient]
[0027] 4-phenylbutyric acid is also called 4-PBA and is a known compound represented by the following formula.
[0028]
[0029] As for the ester of 4-phenylbutyric acid, for example, there can be mentioned an ester formed by dehydration condensation of the carboxyl group of 4-phenylbutyric acid and a monohydric alcohol having 1 to 6 carbon atoms. Specific examples thereof include methyl ester, ethyl ester, n-propyl ester, isopropyl ester, n-butyl ester, isobutyl ester, sec-butyl ester, tert-butyl ester, n-pentyl ester and n-hexyl ester. Among them, methyl ester, ethyl ester, n-propyl ester and isopropyl ester are preferred.
[0030] The salts of 4-phenylbutyric acid and 4-phenylbutyric acid esters are not particularly limited as long as they are pharmacologically acceptable salts. Specific examples include metal salts such as sodium salts, potassium salts, calcium salts, and magnesium salts; inorganic salts such as ammonium salts; organic amine salts such as triethylamine salts and guanidine salts; and the like. Among them, sodium salts and potassium salts are preferred, and sodium salts are more preferred.
[0031] 4-phenylbutyric acid or its ester or a pharmacologically acceptable salt thereof may be a non-solvate or a solvate (eg, a hydrate).
[0032] The content of the component (A) in the aqueous composition according to the present embodiment is not particularly limited, and can be appropriately set according to the types and contents of other blending components, the formulation form, etc. The content of the component (A) is preferably 0.01 to 6 w / v%, more preferably 0.025 to 5 w / v%, further preferably 0.05 to 4 w / v%, and most preferably 0.1 to 3 w / v%, based on the total amount of the aqueous composition according to the present embodiment, from the viewpoint of more significantly exerting the effect produced by the first present invention.
[0033] [(B) ingredient]
[0034] The aqueous composition according to the present embodiment preferably further contains (B) a buffer (also referred to as "component (B)"). By making the aqueous composition further contain component (B), the effect of the first present invention can be more significantly exerted. The buffer includes inorganic buffers and organic buffers, and is not particularly limited as long as it is a buffer that is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable.
[0035] The inorganic buffer is a buffer derived from an inorganic acid. Examples of the inorganic buffer include boric acid buffers, phosphate buffers, and carbonate buffers.
[0036] As the boric acid buffer, boric acid or its salts (alkali metal borate, alkaline earth metal borate, etc.) can be exemplified. As the phosphate buffer, phosphoric acid or its salts (alkali metal phosphate, alkaline earth metal phosphate, etc.) can be exemplified. As the carbonate buffer, carbonic acid or its salts (alkali metal carbonate, alkaline earth metal carbonate, etc.) can be exemplified. In addition, hydrates of borates or phosphates can also be used as boric acid buffers or phosphate buffers. As for more specific examples, as boric acid buffers, boric acid or its salts (sodium borate, potassium tetraborate, potassium metaborate, ammonium borate, borax, etc.) can be exemplified; as phosphate buffers, phosphoric acid or its salts (disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, trisodium phosphate, tripotassium phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate, etc.) can be exemplified; as carbonate buffers, carbonate or its salts (sodium bicarbonate, sodium carbonate, ammonium carbonate, potassium carbonate, calcium carbonate, potassium bicarbonate, magnesium carbonate, etc.) can be exemplified; and so on.
[0037] The organic buffer is a buffer derived from an organic acid or an organic base, and examples of the organic buffer include citric acid buffer, acetic acid buffer, Tris buffer, epsilon-aminocaproic acid buffer, AMPD buffer, and the like.
[0038] As a citric acid buffer, citric acid or its salts (citric acid alkali metal salts, citric acid alkaline earth metal salts, etc.) can be exemplified. As an acetic acid buffer, acetic acid or its salts (acetic acid alkali metal salts, acetic acid alkaline earth metal salts, etc.) can be exemplified. In addition, a hydrate of a citrate or an acetate can also be used as a citric acid buffer or an acetic acid buffer. As for more specific examples, as a citric acid buffer, citric acid or its salts (sodium citrate, potassium citrate, calcium citrate, sodium dihydrogen citrate, disodium citrate, etc.) can be exemplified; as an acetic acid buffer, acetic acid or its salts (ammonium acetate, potassium acetate, calcium acetate, sodium acetate, etc.) can be exemplified; and so on. As a Tris buffer, for example, trometamol or its salts (trometamol hydrochloride, etc.) can be exemplified. As an ε-aminocaproic acid buffer, for example, ε-aminocaproic acid or its salts can be exemplified. As an AMPD buffer, for example, 2-amino-2-methyl-1,3-propanediol or its salts can be exemplified.
[0039] As the buffer, from the viewpoint of more significantly exerting the effect produced by the first present invention, a boric acid buffer (for example, a combination of boric acid and borax), a phosphate buffer (for example, a combination of disodium hydrogen phosphate and sodium dihydrogen phosphate), or a Tris buffer (for example, tromethamine) is preferred, a boric acid buffer is more preferred, boric acid and its salts are further preferred, and a combination of boric acid and borax is further preferred.
[0040] A commercially available buffer can be used as the buffer. The buffer can be used alone or in combination of two or more.
[0041] The content of the component (B) in the aqueous composition according to the present embodiment is not particularly limited, and can be appropriately set according to the type of the component (B), the type and content of other blending components, the use of the aqueous composition, the formulation form, etc. The content of the component (B) is preferably 0.05 to 5.0 w / v%, more preferably 0.08 to 4.5 w / v%, further preferably 0.1 to 4.0 w / v%, and most preferably 0.3 to 3.5 w / v% based on the total amount of the aqueous composition from the viewpoint of more significantly exerting the effect produced by the first present invention.
[0042] The content ratio of the component (B) in the aqueous composition according to the present embodiment relative to the component (A) is not particularly limited, and can be appropriately set according to the types of the components (A) and (B), the types and contents of other blending components, the use of the aqueous composition, and the formulation form. From the viewpoint of more significantly exerting the effect of the first present invention, the content ratio of the component (B) relative to the component (A) is preferably 0.008 to 500 parts by mass, more preferably 0.02 to 180 parts by mass, further preferably 0.02 to 80 parts by mass, and most preferably 0.1 to 35 parts by mass, relative to 1 part by mass of the total content of the component (A) contained in the aqueous composition according to the present embodiment.
[0043] [(C) ingredient]
[0044] The aqueous composition according to the present embodiment preferably further contains (C) a chelating agent (also referred to as "component (C)"). By making the aqueous composition further contain component (C), it can be combined with component (A) to synergistically exert a preservative effect. The chelating agent is not particularly limited as long as it is a chelating agent that is medically, pharmacologically (pharmaceutically) or physiologically acceptable.
[0045] As the chelating agent, for example, ethylenediaminediacetic acid (EDDA), ethylenediaminetriacetic acid, ethylenediaminetetraacetic acid (edetic acid) (EDTA), N-(2-hydroxyethyl)ethylenediaminetriacetic acid (HEDTA), diethylenetriaminepentaacetic acid (DTPA), gluconic acid, and salts thereof, etc. As salts thereof, for example, metal salts such as sodium salts, potassium salts, calcium salts, and magnesium salts can be mentioned.
[0046] The chelating agent is preferably ethylenediaminetetraacetic acid or a salt thereof, more preferably sodium salt of ethylenediaminetetraacetic acid, further preferably disodium ethylenediaminetetraacetate and tetrasodium ethylenediaminetetraacetate, and most preferably disodium ethylenediaminetetraacetate.
[0047] The content of the component (C) in the aqueous composition according to the present embodiment is not particularly limited, and can be appropriately set according to the type of the component (C), the type and content of other blending components, the use of the aqueous composition, the formulation form, etc. The content of the component (C) is preferably 0.001 to 12 w / v%, more preferably 0.003 to 8 w / v%, further preferably 0.006 to 4 w / v%, and most preferably 0.01 to 2 w / v%, based on the total amount of the aqueous composition, from the viewpoint of synergistically exerting the preservation effect in combination with the component (A).
[0048] The content ratio of the component (C) in the aqueous composition according to the present embodiment relative to the component (A) is not particularly limited, and can be appropriately set according to the types of the components (A) and (C), the types and contents of other blending components, the use of the aqueous composition, the formulation form, etc. As the content ratio of the component (C) relative to the component (A), from the viewpoint of synergistically exerting the preservation effect in combination with the component (A), relative to 1 part by mass of the total content of the component (A) contained in the aqueous composition according to the present embodiment, it is preferably 0.0002 to 1200 parts by mass, more preferably 0.0006 to 320 parts by mass, further preferably 0.0015 to 80 parts by mass, and most preferably 0.003 to 20 parts by mass.
[0049] The aqueous composition according to the present embodiment may contain an appropriate amount of a component selected from various pharmacologically active components and physiologically active components in addition to the above components, as long as it is within a range that does not impair the effects of the first present invention. The component is not particularly limited, and examples thereof include antiallergic agents, antihistamines, anti-inflammatory agents, steroids, decongestants, eye muscle regulating agents, vitamins, amino acids, astringents, and the like.
[0050] In the aqueous composition according to the present embodiment, various additives may be appropriately selected according to the conventional method according to the purpose and the formulation form, and one or more additives may be used and contained in an appropriate amount as long as the effect of the first present invention is not impaired. Examples of such additives include carriers, pH adjusters, surfactants, fragrances or cooling agents, thickeners, stabilizers, preservatives, isotonic agents, and the like.
[0051] wait.
[0052] The pH of the aqueous composition according to the present embodiment is not particularly limited as long as it is within the range permitted medically, pharmacologically (pharmaceutically) or physiologically. From the viewpoint of more significantly exerting the effect of the first present invention, the pH of the aqueous composition is preferably 9.0 or less, more preferably 8.5 or less, and even more preferably 8.0 or less. In addition, from the viewpoint of further improving the stability of 4-phenylbutyric acid or its ester or a pharmacologically acceptable salt thereof, the pH of the aqueous composition is preferably 6.0 or more, more preferably 6.5 or more, and even more preferably 7.0 or more.
[0053] The aqueous composition involved in the present embodiment can be adjusted to an osmotic pressure ratio within the range allowed by the organism as needed. The appropriate osmotic pressure ratio can be appropriately set according to the purpose, formulation form, and method of use of the aqueous composition, for example, it can be set to 0.4 to 5.0. The osmotic pressure ratio is based on the 18th revised edition of the Japanese Pharmacopoeia, and is set to the ratio of the osmotic pressure of the sample to 286mOsm (the osmotic pressure of 0.9w / v% sodium chloride aqueous solution). The osmotic pressure is measured with reference to the osmotic pressure determination method (freezing point depression method) recorded in the Japanese Pharmacopoeia. It should be noted that, with respect to the standard solution for osmotic pressure ratio determination (0.9w / v% sodium chloride aqueous solution), sodium chloride (Japanese Pharmacopoeia standard reagent) can be dried at 500 to 650°C for 40 to 50 minutes, placed in a desiccator (silica gel) for cooling, accurately weighing 0.900g of the sodium chloride, and dissolving it in purified water to accurately prepare 100mL, or a commercially available standard solution for osmotic pressure ratio determination (0.9w / v% sodium chloride aqueous solution) can be used.
[0054] The viscosity of the aqueous composition involved in this embodiment is not particularly limited as long as it is within the range permitted medically, pharmacologically (pharmaceutically) or physiologically. The viscosity of the aqueous composition involved in this embodiment, for example, can be 1 to 10000 mPa·s at 20°C measured using a rotational viscometer (TV-20 viscometer, manufactured by Toki Sangyo Co., Ltd., rotor; 1°34'×R24).
[0055] The aqueous composition according to the present embodiment can be prepared, for example, by adding and mixing the (A) component and other components added as needed at a desired content. Specifically, it can be prepared, for example, by dissolving or suspending the above components in purified water and sterilizing them by filtration sterilization or the like.
[0056] When the aqueous composition involved in the present embodiment is an ophthalmic composition, it can be used as, for example, eye drops (also called eye drops or eye drops; in addition, eye drops include eye drops that can be dropped into the eyes while wearing contact lenses), artificial tears, eye washes (also called eye washes or eye washes; in addition, eye washes include eye washes that can be washed when wearing contact lenses). It should be noted that "contact lenses" include hard contact lenses and soft contact lenses (including both ionic and non-ionic, and including both silicone hydrogel contact lenses and non-silicone hydrogel contact lenses).
[0057] Since the aqueous composition involved in this embodiment contains sodium 4-phenylbutyrate as an active ingredient, it can be suitably used as a preventive, inhibitory or therapeutic agent for myopia. In addition, since the aqueous composition involved in this embodiment contains sodium 4-phenylbutyrate as an active ingredient, it can also be suitably used as a preventive, inhibitory or therapeutic agent for presbyopia.
[0058] In order to more significantly exert the effect of the first present invention, the aqueous composition of this embodiment is preferably an ophthalmic composition, and more preferably an eye drop (including eye drops that can be dropped while wearing contact lenses). When the aqueous composition of this embodiment is an eye drop, its usage and dosage are not particularly limited, as long as it is an usage and dosage that exerts the effect and has few side effects. For example, in the case of adults (over 15 years old) and children over 7 years old, the following method can be exemplified: 1 to 4 times or 5 to 6 times a day, and 1 to 3 drops, 1 to 2 drops, or 2 to 3 drops per time.
[0059] [container]
[0060] The aqueous composition according to the present embodiment is provided in a container in which a part or all of the part in contact with the aqueous composition is formed of a resin containing polyolefin (hereinafter also referred to as "resin according to the present embodiment"). As the resin containing polyolefin, for example, a resin containing polyethylene (PE), polypropylene (PP), ethylene-propylene copolymer, ethylene-vinyl acetate copolymer, polymethylpentene, cyclic olefin polymer (COP), cyclic olefin copolymer (COC), and a combination thereof can be cited.
[0061] Examples of the polyethylene include high-density polyethylene (HDPE), low-density polyethylene (LDPE) and linear low-density polyethylene (LLDPE).
[0062] The cyclic olefin polymer is not particularly limited, as long as it contains a polymer formed by copolymerizing a single cyclic olefin, or a polymer formed by copolymerizing two or more cyclic olefins, or their hydrogenates. The cyclic olefin polymer preferably contains a ring-opening polymer of a cyclic olefin or its hydrogenate. In addition, the cyclic olefin polymer preferably contains an amorphous polymer.
[0063] The cyclic olefin copolymer is not particularly limited as long as it contains a polymer obtained by copolymerizing a cyclic olefin and a non-cyclic olefin, or a hydrogenated product thereof.
[0064] Examples of cyclic olefins include monocyclic or polycyclic cycloalkanes, monocyclic or polycyclic cycloolefins, and derivatives thereof having vinyl groups. Examples of cyclic olefins include norbornene, tetracyclododecene, and derivatives thereof. Examples of acyclic olefins include α-olefins such as ethylene, propylene, 1-butene, 1-pentene, and 1-hexene.
[0065] As cyclic olefin polymer, with regard to the viewpoint of more significantly bringing into play the effect produced by the 1st present invention, preferably contain the polymer of cyclic olefin with norbornene skeleton or its hydride.As cyclic olefin copolymer, with regard to the viewpoint of more significantly bringing into play the effect produced by the 1st present invention, preferably make the polymer formed by copolymerization of norbornene and ethylene.It should be noted that, in the polymer formed by copolymerization of cyclic olefin and non-cyclic olefin, also can comprise other monomers as the constituent component of this polymer.
[0066] The resin involved in this embodiment is preferably a resin containing at least one selected from the group consisting of polyethylene (PE), polypropylene (PP) and cyclic olefin copolymer (COC), and more preferably a resin containing only polyethylene, a resin containing only polypropylene, and a resin containing a cyclic olefin copolymer and polyethylene.
[0067] When the resin according to the present embodiment is a resin containing a cyclic olefin copolymer and polyethylene, the content ratio of the cyclic olefin copolymer to the polyethylene in the resin may be, for example, 50:50 to 95:5, 55:45 to 90:10, or 60:40 to 85:15.
[0068] The resin involved in the present embodiment may also include, for example, polycarbonate, (meth) acrylic polymer, polystyrene (PS), polyethylene naphthalate (PEN), polybutylene terephthalate (PBT), polyethylene terephthalate (PET), and other polymers such as polyarylate. In addition, the resin involved in the present embodiment may also include additives such as stabilizers, modifiers, colorants, ultraviolet absorbers, metal oxides, oxygen absorbers, antibacterial agents, plasticizers, and glass fibers.
[0069] The type of container may be a container commonly used in the ophthalmology field, and specifically, an eye drop container may be mentioned. The portion of the container that contacts the aqueous composition may be, for example, an inner plug, an inner plug having a hole, or an inner surface of the container (the innermost layer when the container is a structure formed of multiple layers).
[0070] The portion of the container that contacts the aqueous composition is partially or entirely formed of a resin containing polyolefin. For example, when the container is a container having an open hole plug (nozzle), only the open hole plug portion may be formed of the resin involved in this embodiment, or the receiving portion other than the open hole plug may be formed of the resin involved in this embodiment, or the entire container may be formed of the resin involved in this embodiment.
[0071] As long as a part of the container in contact with the aqueous composition is formed by the resin involved in this embodiment, it is sufficient. However, from the viewpoint of more significantly exerting the effect produced by the first present invention, it is preferred that the part in contact with the aqueous composition is formed entirely by the resin involved in this embodiment. When a part of the container is formed by the resin involved in this embodiment, there is no particular limitation on the type of resin forming the other part, and examples thereof include polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polyethylene naphthalate (PEN), polystyrene (PS), polyarylate (PAR), polycarbonate (PC), polyimide (PI), acrylonitrile-butadiene-styrene (ABS), copolymers of monomers constituting these, and resins obtained by mixing two or more of these.
[0072] The shape and capacity of the container are not particularly limited and can be appropriately set according to the purpose. In addition, the container can be a container for accommodating multiple-use amounts of the aqueous composition (multiple-dose container) or a container for accommodating a single-use amount of the aqueous composition (single-dose container).
[0073] When the container is a multi-dose container, the capacity may be, for example, 1.5 to 7.5 mL, 2 to 6 mL, or 2.5 to 5.0 mL. When the container is a single-dose container, the capacity may be, for example, 0.1 to 1.0 mL, 0.2 to 0.9 mL, or 0.3 to 0.8 mL.
[0074] The aqueous composition according to this embodiment may be provided as an aqueous composition in a container. In addition, the first present invention may also be understood as a pharmaceutical product (ophthalmic product such as eye drops) containing the aqueous composition of the first present invention in a container.
[0075] [First embodiment of the present invention]
[0076] Hereinafter, the first present invention will be specifically described based on test examples, but the first present invention is not limited thereto. In addition, the unit of each component in the table is w / v% unless otherwise specified.
[0077] [Test Example 1: Stability test in multi-dose container]
[0078] <Preparation of drug products>
[0079] Each aqueous composition (preparation 1-0 to 1-4) shown in Table 1-1 was prepared by a conventional method, and 5 mL of each was filled into 5 mL capacity polyethylene (PE), polypropylene (PP) and polyethylene terephthalate (PET) multidose containers.
[0080] <Stability of Sodium 4-phenylbutyrate>
[0081] Sodium 4-phenylbutyrate was quantified by liquid chromatography. 10 μL of a 0.05 w / v% sodium 4-phenylbutyrate solution was used as a standard solution, and 10 μL of a preparation diluted 10 times with a mobile phase was used as a sample solution. The standard solution and the sample solution were respectively supplied to a reverse phase column (YMC-Pack ODS-A (ID4.6 mm×150 mm, 5 μm), manufactured by YMC Co., Ltd.) maintained at 30°C, and eluted using a mobile phase 0.2% formic acid solution / acetonitrile mixture. Detection was performed using an ultraviolet spectrophotometer (measurement wavelength: 260 nm). Then, the peak area of sodium 4-phenylbutyrate was measured for the standard solution and the sample solution, respectively, and the concentration of sodium 4-phenylbutyrate was calculated for each preparation just after preparation and after storage at 60°C for 1 week according to the following formula 1. The results when the concentration just after preparation was set to 100 are shown in Table 1-2.
[0082] Formula 1: Concentration of sodium 4-phenylbutyrate (w / v%) = 0.05 × (peak area of 4-phenylbutyric acid in sample solution / peak area of 4-phenylbutyric acid in standard solution) × 10
[0083] <Determination of total impurities>
[0084] The total impurities were determined by liquid chromatography. 50 μL of the preparation diluted 100 times with purified water was used as the standard solution, and 50 μL of the preparation was used as the sample solution. The standard solution and the sample solution were respectively supplied to a reverse phase column (Inertsil Ph-3HP (ID4.6 mm×250 mm, 3 μm), manufactured by GL Science Co., Ltd.) maintained at 45°C, and eluted using a gradient program of mobile phase A: water / acetic acid (99:1) and mobile phase B: acetonitrile / acetic acid (99:1). Detection was performed using an ultraviolet spectrophotometer (measurement wavelength: 254 nm). Then, for the standard solution, the peak area of sodium 4-phenylbutyrate was measured, and for the sample solution, the peak area of each component other than sodium 4-phenylbutyrate was measured. For each preparation just after preparation and after storage at 60°C for 1 week, the ratio of each impurity to sodium 4-phenylbutyrate was calculated according to the following formula 2, and the sum was calculated. It should be noted that the measurement range of the area was set to within about twice the retention time of sodium 4-phenylbutyrate. In addition, preparation 1-0 was used as the base. The results when the total impurity amount immediately after preparation was set to 1 are shown in Table 1-3.
[0085] Formula 2: Ratio of each impurity to 4-phenylbutyric acid = (peak area of components other than 4-phenylbutyric acid - peak area of components other than 4-phenylbutyric acid in the base) / peak area of 4-phenylbutyric acid
[0086] [Table 1-1]
[0087] Ingredient name Preparation 1-0 Preparation 1-1 Preparation 1-2 Preparations 1-3 Preparation 1-3′ Preparation 1-3" Preparations 1-4 Sodium 4-phenylbutyrate 0 0.5 0.5 0.5 0.5 0.5 0.5 Boric acid 1 1 0 1 1 1 1 Borax 0.15 0.15 0 0.15 0.15 0.15 0.15 Sodium dihydrogen phosphate 0 0 0.05 0 0 0 0 Disodium hydrogen phosphate 0 0 0.7 0 0 0 0 Disodium EDTA 0.03 0.03 0.03 0.03 0.03 0.03 0.03 Hydrochloric acid / sodium hydroxide Moderate Moderate Moderate Moderate Moderate Moderate Moderate Purified water margin margin margin margin margin margin margin total 100mL 100mL 100mL 100mL 100mL 100mL 100mL pH 7.5 7.5 7.5 5 6 8.5 10
[0088] [Table 1-2]
[0089]
[0090] [Table 1-3]
[0091]
[0092] According to Table 1-2, no difference was observed in the stability of sodium 4-phenylbutyrate itself between the container resins. On the other hand, according to Table 1-3, it can be confirmed that the preparations contained in polyethylene resins and polypropylene resins suppress the generation of impurities compared to the preparations contained in polyethylene terephthalate resins.
[0093] [Test Example 2: Stability test in a single-dose container]
[0094] <Preparation of Preparation>
[0095] The aqueous composition (preparation 2-1) shown in Table 1-4 was prepared by a conventional method, and 0.5 mL was filled into a 0.5 mL capacity polyethylene (PE) single-dose container and a single-dose container made of a resin mixed with a cyclic olefin copolymer (COC) and polyethylene (PE).
[0096] <Stability of Sodium 4-phenylbutyrate>
[0097] Sodium 4-phenylbutyrate was quantified by liquid chromatography. 20 μL of 0.02 w / v% sodium 4-phenylbutyrate solution was used as the standard solution, and 20 μL of preparation 2-1 diluted 10 times with the mobile phase was used as the sample solution. The standard solution and the sample solution were respectively supplied to a reverse phase column (YMC-Pack ODS-A (ID4.6 mm×150 mm, 5 μm), manufactured by YMC Co., Ltd.) maintained at 30°C, and eluted using a mobile phase 0.2% formic acid solution / acetonitrile mixture. Detection was performed using an ultraviolet spectrophotometer (measurement wavelength: 260 nm). Then, the peak area of sodium 4-phenylbutyrate was measured for the standard solution and the sample solution, respectively, and the concentration of sodium 4-phenylbutyrate was calculated for the preparation 2-1 just after preparation and after storage at 40°C for 1 month according to the following formula 3. The results when the concentration just after preparation was set to 100 are shown in Table 1-5.
[0098] Formula 3: Concentration of sodium 4-phenylbutyrate (w / v%) = 0.02 × (peak area of 4-phenylbutyric acid in sample solution / peak area of 4-phenylbutyric acid in standard solution) × 10
[0099] <Determination of total impurities>
[0100] The total impurities were determined by liquid chromatography. 80 μL of the preparation diluted 100 times with purified water was used as the standard solution, and 80 μL of the preparation was used as the sample solution. The standard solution and the sample solution were respectively supplied to a reverse phase column (Inertsil Ph-3 (ID4.6 mm×250 mm, 5 μm), manufactured by GL Science Co., Ltd.) maintained at 40°C, and eluted using a gradient program of mobile phase A: water / acetic acid (99:1) and mobile phase B: acetonitrile / acetic acid (99:1). Detection was performed using an ultraviolet spectrophotometer (measurement wavelength: 254 nm). Then, for the standard solution, the peak area of sodium 4-phenylbutyrate was measured, and for the sample solution, the peak area of each component other than sodium 4-phenylbutyrate was measured. For the preparation 2-1 just after preparation and after storage at 40°C for 1 month, the ratio of each impurity to sodium 4-phenylbutyrate was calculated according to the following formula 4, and the sum was calculated. The measurement range of the area was set to a time within about twice the retention time of sodium 4-phenylbutyrate. The results when the total impurity amount immediately after the preparation was set to 1 are shown in Table 1-6.
[0101] Formula 4: Ratio of each impurity to 4-phenylbutyric acid = Peak area of components other than 4-phenylbutyric acid / Peak area of 4-phenylbutyric acid
[0102] [Table 1-4]
[0103] Preparation 2-1 Sodium 4-phenylbutyrate 0.1 Boric acid 1 Borax 0.07 Sodium chloride 0.3 Potassium chloride 0.16 Hydrochloric acid / sodium hydroxide Moderate Purified water margin total 100mL pH 7
[0104] [Table 1-5]
[0105]
[0106] [Table 1-6]
[0107]
[0108] According to Table 1-5, no difference was observed in the stability of sodium 4-phenylbutyrate itself between the container resins. In addition, according to Table 1-6, it can be confirmed that the preparations contained in the polyethylene resin and the resin containing the cyclic olefin copolymer and polyethylene all suppressed the generation of impurities.
[0109] The description of the first present invention is completed above, and the description of the second present invention will be continued.
[0110] Second Invention
[0111] The second present invention relates to an aqueous composition. Background Art
[0113] It is known that sodium 4-phenylbutyrate is metabolized to phenylacetic acid in the body and excreted into urine by combining with glutamic acid, and is used as a therapeutic drug for urea cycle disorders (Non-patent Document 1). Recently, it has been reported that sodium 4-phenylbutyrate is useful in preventing or treating eye diseases such as myopia or presbyopia (e.g., Patent Documents 1 and 2).
[0114] Prior art literature
[0115] Patent Literature
[0116] Patent Document 1: International Publication No. 2018 / 164113
[0117] Patent Document 2: International Publication No. 2020 / 129965
[0118] Non-patent literature
[0119] Non-patent document 1: Buphenyl (registered trademark) tablets 500 mg Buphenyl (registered trademark) granules 94% attachment
[0120] Second content of the present invention
[0121] Second Problem to be Solved by the Invention
[0122] Therapeutic drugs for urea cycle disorders containing sodium 4-phenylbutyrate as an active ingredient are commercially available in the form of tablets and granules suitable for oral administration. On the other hand, aqueous compositions such as eye drops are required to have a certain preservation effect, but there is no report on the preservation effect of liquid preparations containing sodium 4-phenylbutyrate. A second object of the present invention is to provide an aqueous composition containing sodium 4-phenylbutyrate and having excellent preservation effect.
[0123] Technical means for solving the problem of the second invention
[0124] The inventors of the present application have conducted intensive studies to solve the above problems and unexpectedly found that the preservation effect of the aqueous composition is synergistically enhanced by adding disodium ethylenediaminetetraacetate as a chelating agent to an aqueous composition containing sodium 4-phenylbutyrate. The second present invention is based on this finding and provides the following inventions. [1]
[0126] An aqueous composition comprising (A) 4-phenylbutyric acid or an ester thereof or a pharmacologically acceptable salt thereof and (B) a chelating agent. [2]
[0128] The aqueous composition according to [1] contains 0.0002 to 1200 parts by mass of the component (B) based on 1 part by mass of the total content of the component (A). [3]
[0130] The aqueous composition according to [1] or [2] further comprises (C) a buffer. [4]
[0132] The aqueous composition according to any one of [1] to [3], wherein the pH is 5.0 or more and 9.0 or less.
[0133] Effect of the Second Invention
[0134] According to the second present invention, an aqueous composition containing sodium 4-phenylbutyrate and having excellent preservative efficacy can be provided.
[0135] Second Embodiment of the Invention
[0136] Hereinafter, specific embodiments of the second present invention will be described in detail. However, the second present invention is not limited to the following embodiments.
[0137] The aqueous composition according to the present embodiment contains (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof (also referred to as "component (A)").
[0138] [(A) ingredient]
[0139] 4-phenylbutyric acid is also called 4-PBA and is a known compound represented by the following formula.
[0140]
[0141] As for the ester of 4-phenylbutyric acid, for example, there can be mentioned an ester formed by dehydration condensation of the carboxyl group of 4-phenylbutyric acid and a monohydric alcohol having 1 to 6 carbon atoms. Specific examples thereof include methyl ester, ethyl ester, n-propyl ester, isopropyl ester, n-butyl ester, isobutyl ester, sec-butyl ester, tert-butyl ester, n-pentyl ester and n-hexyl ester. Among them, methyl ester, ethyl ester, n-propyl ester and isopropyl ester are preferred.
[0142] The salts of 4-phenylbutyric acid and 4-phenylbutyric acid esters are not particularly limited as long as they are pharmacologically acceptable salts. Specific examples include metal salts such as sodium salts, potassium salts, calcium salts, and magnesium salts; inorganic salts such as ammonium salts; organic amine salts such as triethylamine salts and guanidine salts; and the like. Among them, sodium salts and potassium salts are preferred, and sodium salts are more preferred.
[0143] 4-phenylbutyric acid or its ester or a pharmacologically acceptable salt thereof may be a non-solvate or a solvate (eg, a hydrate).
[0144] The content of the component (A) in the aqueous composition according to the present embodiment is not particularly limited and can be appropriately set according to the types and contents of other blending components, the formulation form, etc. The content of the component (A) is preferably 0.01 to 6 w / v%, more preferably 0.025 to 5 w / v%, further preferably 0.05 to 4 w / v%, and most preferably 0.1 to 3 w / v%, based on the total amount of the aqueous composition according to the present embodiment, from the viewpoint of more significantly exerting the effect produced by the second present invention.
[0145] [(B) ingredient]
[0146] The aqueous composition according to the present embodiment further contains (B) a chelating agent (also referred to as "component (B)"). The chelating agent is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable.
[0147] As the chelating agent, for example, ethylenediaminediacetic acid (EDDA), ethylenediaminetriacetic acid, ethylenediaminetetraacetic acid (edetic acid) (EDTA), N-(2-hydroxyethyl)ethylenediaminetriacetic acid (HEDTA), diethylenetriaminepentaacetic acid (DTPA), gluconic acid, and salts thereof, etc. As salts thereof, for example, metal salts such as sodium salts, potassium salts, calcium salts, and magnesium salts can be mentioned.
[0148] The chelating agent is preferably ethylenediaminetetraacetic acid or a salt thereof, more preferably sodium salt of ethylenediaminetetraacetic acid, further preferably disodium ethylenediaminetetraacetate and tetrasodium ethylenediaminetetraacetate, and most preferably disodium ethylenediaminetetraacetate.
[0149] The content of the component (B) in the aqueous composition according to the present embodiment is not particularly limited, and can be appropriately set according to the type of the component (B), the type and content of other blending components, the use of the aqueous composition, the formulation form, etc. The content of the component (B) is preferably 0.001 to 12 w / v%, more preferably 0.003 to 8 w / v%, further preferably 0.006 to 4 w / v%, and most preferably 0.01 to 2 w / v%, based on the total amount of the aqueous composition, from the viewpoint of synergistically exerting the preservation effect in combination with the component (A).
[0150] The content ratio of the component (B) in the aqueous composition according to the present embodiment relative to the component (A) is not particularly limited, and can be appropriately set according to the types of the components (A) and (B), the types and contents of other blending components, the use of the aqueous composition, the formulation form, etc. As the content ratio of the component (B) relative to the component (A), from the viewpoint of more synergistically exerting the preservation effect, relative to 1 part by mass of the total content of the component (A) contained in the aqueous composition according to the present embodiment, it is preferably 0.0002 to 1200 parts by mass, more preferably 0.0006 to 320 parts by mass, further preferably 0.0015 to 80 parts by mass, and most preferably 0.003 to 20 parts by mass.
[0151] [(C) ingredient]
[0152] The aqueous composition according to the present embodiment preferably further contains (C) a buffer (also referred to as "component (C)"). By making the aqueous composition further contain component (C), the effect of the second present invention can be more significantly exerted. The buffer includes inorganic buffers and organic buffers, and is not particularly limited as long as it is a buffer that is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable.
[0153] The inorganic buffer is a buffer derived from an inorganic acid. Examples of the inorganic buffer include boric acid buffers, phosphate buffers, and carbonate buffers.
[0154] As the boric acid buffer, boric acid or its salts (alkali metal borate, alkaline earth metal borate, etc.) can be exemplified. As the phosphate buffer, phosphoric acid or its salts (alkali metal phosphate, alkaline earth metal phosphate, etc.) can be exemplified. As the carbonate buffer, carbonic acid or its salts (alkali metal carbonate, alkaline earth metal carbonate, etc.) can be exemplified. In addition, hydrates of borates or phosphates can also be used as boric acid buffers or phosphate buffers. As for more specific examples, as boric acid buffers, boric acid or its salts (sodium borate, potassium tetraborate, potassium metaborate, ammonium borate, borax, etc.) can be exemplified; as phosphate buffers, phosphoric acid or its salts (disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, trisodium phosphate, tripotassium phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate, etc.) can be exemplified; as carbonate buffers, carbonate or its salts (sodium bicarbonate, sodium carbonate, ammonium carbonate, potassium carbonate, calcium carbonate, potassium bicarbonate, magnesium carbonate, etc.) can be exemplified; and so on.
[0155] The organic buffer is a buffer derived from an organic acid or an organic base. Examples of the organic buffer include citric acid buffer, acetic acid buffer, Tris buffer, ε-aminocaproic acid buffer, and AMPD buffer.
[0156] As a citric acid buffer, citric acid or its salts (citric acid alkali metal salts, citric acid alkaline earth metal salts, etc.) can be cited. As an acetic acid buffer, acetic acid or its salts (acetic acid alkali metal salts, acetic acid alkaline earth metal salts, etc.) can be cited. In addition, a hydrate of a citrate or an acetate can also be used as a citric acid buffer or an acetic acid buffer. As a more specific example, as a citric acid buffer, citric acid or its salts (sodium citrate, potassium citrate, calcium citrate, sodium dihydrogen citrate, disodium citrate, etc.) can be cited; as an acetic acid buffer, acetic acid or its salts (ammonium acetate, potassium acetate, calcium acetate, sodium acetate, etc.) can be cited. As a Tris buffer, for example, tromethamine or its salts (tromethamine hydrochloride, etc.) can be cited. As an ε-aminocaproic acid buffer, for example, ε-aminocaproic acid or its salts can be cited. As an AMPD buffer, for example, 2-amino-2-methyl-1,3-propanediol or its salts can be cited.
[0157] As the buffer, from the viewpoint of more significantly exerting the effect produced by the second present invention, a boric acid buffer (for example, a combination of boric acid and borax), a phosphate buffer (for example, a combination of disodium hydrogen phosphate and sodium dihydrogen phosphate), or a Tris buffer (for example, tromethamine) is preferred, a boric acid buffer is more preferred, boric acid and its salts are further preferred, and a combination of boric acid and borax is further preferred.
[0158] A commercially available buffer can be used as the buffer. The buffer can be used alone or in combination of two or more.
[0159] The content of the component (C) in the aqueous composition according to the present embodiment is not particularly limited, and can be appropriately set according to the type of the component (C), the type and content of other blending components, the use of the aqueous composition, the formulation form, etc. The content of the component (C) is preferably 0.05 to 5.0 w / v%, more preferably 0.08 to 4.5 w / v%, further preferably 0.1 to 4.0 w / v%, and most preferably 0.3 to 3.5 w / v%, based on the total amount of the aqueous composition, from the viewpoint of more significantly exerting the effect produced by the second present invention.
[0160] The content ratio of the component (C) in the aqueous composition according to the present embodiment relative to the component (A) is not particularly limited, and can be appropriately set according to the types of the components (A) and (C), the types and contents of other blending components, the use of the aqueous composition, and the formulation form. From the viewpoint of more significantly exerting the effect of the second present invention, the content ratio of the component (C) relative to the component (A) is preferably 0.008 to 500 parts by mass, more preferably 0.02 to 180 parts by mass, further preferably 0.03 to 80 parts by mass, and most preferably 0.1 to 35 parts by mass, relative to 1 part by mass of the total content of the component (A) contained in the aqueous composition according to the present embodiment.
[0161] The aqueous composition according to the present embodiment may contain an appropriate amount of a component selected from various pharmacologically active components and physiologically active components in addition to the above components, as long as it is within a range that does not impair the effects of the second present invention. The component is not particularly limited, and examples thereof include antiallergic agents, antihistamines, anti-inflammatory agents, steroids, decongestants, eye muscle regulating agents, vitamins, amino acids, astringents, and the like.
[0162] In the aqueous composition according to the present embodiment, various additives may be appropriately selected according to the conventional method according to the purpose and the formulation form, and one or more additives may be used and contained in an appropriate amount as long as the effect of the second present invention is not impaired. Such additives include, for example, carriers, pH adjusters, surfactants, fragrances or cooling agents, thickeners, stabilizers, preservatives, isotonic agents, etc.
[0163] The pH of the aqueous composition involved in this embodiment is not particularly limited as long as it is within the range permitted medically, pharmacologically (pharmaceutically) or physiologically. From the viewpoint of more significantly exerting the effect of the second present invention, the pH of the aqueous composition is preferably 9.0 or less, more preferably 8.5 or less, and even more preferably 8.0 or less. In addition, from the viewpoint of further improving the stability of 4-phenylbutyric acid or its ester or a pharmacologically acceptable salt thereof, the pH of the aqueous composition is preferably 5.0 or more, more preferably 5.5 or more, and even more preferably 6.0 or more.
[0164] The aqueous composition involved in the present embodiment can be adjusted to an osmotic pressure ratio within the range allowed by the organism as needed. The appropriate osmotic pressure ratio can be appropriately set according to the purpose, formulation form, and method of use of the aqueous composition, for example, it can be set to 0.4 to 5.0. The osmotic pressure ratio is based on the 18th revised edition of the Japanese Pharmacopoeia, and is set to the ratio of the osmotic pressure of the sample to 286mOsm (the osmotic pressure of 0.9w / v% sodium chloride aqueous solution). The osmotic pressure is measured with reference to the osmotic pressure determination method (freezing point depression method) recorded in the Japanese Pharmacopoeia. It should be noted that, with respect to the standard solution for osmotic pressure ratio determination (0.9w / v% sodium chloride aqueous solution), sodium chloride (Japanese Pharmacopoeia standard reagent) can be dried at 500 to 650°C for 40 to 50 minutes, placed in a desiccator (silica gel) for cooling, accurately weighing 0.900g of the sodium chloride, and dissolving it in purified water to accurately prepare 100mL, or a commercially available standard solution for osmotic pressure ratio determination (0.9w / v% sodium chloride aqueous solution) can be used.
[0165] The viscosity of the aqueous composition involved in this embodiment is not particularly limited as long as it is within the range permitted medically, pharmacologically (pharmaceutically) or physiologically. The viscosity of the aqueous composition involved in this embodiment can be, for example, 1 to 10,000 at 20° C. measured using a rotational viscometer (TV-20 viscometer, manufactured by Toki Sangyo Co., Ltd., rotor; 1°34'×R24).
[0166] The aqueous composition of the present embodiment can be prepared, for example, by adding and mixing component (A), component (B), and other components added as needed at the desired content. Specifically, it can be prepared, for example, by dissolving or suspending the above components in purified water and sterilizing them by filtration sterilization or the like.
[0167] When the aqueous composition involved in the present embodiment is an ophthalmic composition, it can be used as, for example, eye drops (also called eye drops or eye drops; in addition, eye drops include eye drops that can be dropped into the eyes while wearing contact lenses), artificial tears, eye washes (also called eye washes or eye washes; in addition, eye washes include eye washes that can be washed when wearing contact lenses). It should be noted that "contact lenses" include hard contact lenses and soft contact lenses (including both ionic and non-ionic, and including both silicone hydrogel contact lenses and non-silicone hydrogel contact lenses).
[0168] Since the aqueous composition involved in this embodiment contains sodium 4-phenylbutyrate as an active ingredient, it can be suitably used as a preventive, inhibitory or therapeutic agent for myopia. In addition, since the aqueous composition involved in this embodiment contains sodium 4-phenylbutyrate as an active ingredient, it can also be suitably used as a preventive, inhibitory or therapeutic agent for presbyopia.
[0169] In order to more significantly exert the effect of the second present invention, the aqueous composition according to this embodiment is preferably an ophthalmic composition, and more preferably an eye drop (including eye drops that can be dropped while wearing contact lenses). When the aqueous composition according to this embodiment is an eye drop, its usage and dosage are not particularly limited as long as the effect is exerted and the side effects are few. For example, in the case of adults (over 15 years old) and children over 7 years old, the following method can be exemplified: 1 to 4 times or 5 to 6 times a day, and 1 to 3 drops, 1 to 2 drops, or 2 to 3 drops are used at a time.
[0170] The aqueous composition involved in the present embodiment can be accommodated in any container and provided. There is no particular restriction on the container for accommodating the aqueous composition involved in the present embodiment, for example, it can be made of glass, or it can also be made of plastic. It is preferably made of plastic. As plastic, for example, polyolefin resins such as polyethylene, polypropylene, cyclic olefin copolymers, and mixtures of more than two of them, polyester resins such as polyethylene terephthalate, polybutylene terephthalate, polyethylene naphthalate, and mixtures of more than two of them can be cited. As the material of the container, from the perspective of further improving the effect of the second present invention, polyolefin resins are more preferred. For example, other polymers such as polycarbonate, (meth) acrylic polymer, polystyrene (PS), and polyarylate may also be included in the plastic. In addition, additives such as stabilizers, modifiers, colorants, ultraviolet absorbers, metal oxides, oxygen absorbers, antibacterial agents, plasticizers, and glass fibers may also be included in the plastic. In addition, the container for accommodating the aqueous composition involved in the present embodiment may also use elastomers such as styrene-based thermoplastic elastomers and styrene-butadiene-based thermoplastic elastomers. In addition, the container for accommodating the aqueous composition involved in the present embodiment can be a transparent container that can visually recognize the interior of the container, or it can be an opaque container that is difficult to visually recognize the interior of the container. Preferably, it is a transparent container. Here, "transparent container" includes both colorless transparent containers and colored transparent containers.
[0171] The nozzle may also be installed in the container for accommodating the aqueous composition involved in the present embodiment. There is no particular restriction on the material of the nozzle, for example, it may be made of glass, or it may be made of plastic. It is preferably made of plastic. As plastic, for example, polyolefin resins such as polyethylene, polypropylene, cyclic olefin copolymers, and mixtures of more than two of them, polyester resins such as polyethylene terephthalate, polybutylene terephthalate, polyethylene naphthalate, and mixtures of more than two of them may be cited. As the material of the nozzle, polyolefin resins are more preferred from the viewpoint of further improving the effect of the second present invention. For example, other polymers such as polycarbonate, (meth) acrylic polymer, polystyrene (PS), and polyarylate may also be included in the plastic. In addition, additives such as stabilizers, modifiers, colorants, ultraviolet absorbers, metal oxides, oxygen absorbers, antibacterial agents, plasticizers, and glass fibers may also be included in the plastic. In addition, silicone may also be used for the nozzle installed in the container for accommodating the aqueous composition involved in the present embodiment.
[0172] The shape and capacity of the container are not particularly limited and can be appropriately set according to the purpose. In addition, the container can be a container for accommodating multiple-use amounts of the aqueous composition (multiple-dose container) or a container for accommodating a single-use amount of the aqueous composition (single-dose container).
[0173] When the container is a multi-dose container, the capacity may be, for example, 1.5 to 7.5 mL, 2.0 to 6.0 mL, or 2.5 to 5.0 mL. When the container is a single-dose container, the capacity may be, for example, 0.1 to 1.0 mL, 0.2 to 0.9 mL, or 0.3 to 0.8 mL.
[0174] The aqueous composition according to this embodiment may be provided as an aqueous composition in a container. In addition, the second present invention may also be understood as a pharmaceutical product (ophthalmic product such as eye drops) containing the aqueous composition of the second present invention in a container.
[0175] Second Embodiment of the Invention
[0176] Hereinafter, the second present invention will be specifically described based on test examples, but the second present invention is not limited thereto. In addition, the unit of each component in the table is w / v% unless otherwise specified.
[0177] [Test Example 1: Preservation Effectiveness Test]
[0178] The aqueous compositions shown in Table 2-1 were prepared by conventional methods and sterilized by filtration using a 0.2 μm membrane filter. The units of the components in Table 2-1 are w / v%. Then, the preservation efficacy test of each aqueous composition was implemented based on the 18th revised edition of the Japanese Pharmacopoeia. Pseudomonas aeruginosa was inoculated on the surface of a Soybean-Casein Digest slant culture medium and cultured at 30-35°C for 24 hours. The cultured cells were aseptically collected with a platinum loop and suspended in an appropriate amount of sterilized physiological saline to prepare a 1×10 7 CFU / mL of viable bacteria suspension. It should be noted that the number of viable bacteria in the bacterial suspension was determined by culturing separately. Next, 10 mL of each prepared aqueous composition was filled into each 15 mL centrifuge tube (PET). In each of these aqueous compositions, the number of viable bacteria (final concentration) was about 5×10 5 The bacterial suspension is inoculated in the form of CFU / mL and stirred thoroughly to prepare a sample. The sample containing bacteria is stored at 20-25°C for 7 days. Then, the sample containing bacteria is adjusted to a concentration suitable for counting, the bacteria are recovered according to the agar pouring method, and the number of colonies observed is counted after culturing at 30-35°C for 2-3 days in a tryptic soy agar medium. The number of live bacteria just after inoculation is compared with the number of live bacteria in the sample after 7 days of storage, and the reduction in the number of bacteria is calculated as the preservation efficacy (logarithmic reduction value). The results are shown in Table 2-1.
[0179] [Table 2-1]
[0180] Ingredient name Comparative Example 1 Comparative Example 2 Comparative Example 3 Example 1 Sodium 4-phenylbutyrate 0 0 2 2 Boric acid 0.5 0.5 0.5 0.5 Borax 0.025 0.025 0.025 0.025 Disodium EDTA 0 0.03 0 0.03 Hydrochloric acid / sodium hydroxide Moderate Moderate Moderate Moderate Purified water margin margin margin margin total 100mL 100mL 100mL 100mL pH 7.5 7.5 7.5 7.5 Preservation efficacy (logarithmic reduction value) 1.3 1.7 2.9 >4.7
[0181] It was confirmed that in the aqueous composition containing sodium 4-phenylbutyrate and disodium ethylenediaminetetraacetate, the inoculated bacteria were reduced to below the detection limit, and the preservation efficacy (logarithmic reduction value) value was greater than 4.7 (Example 1). In the aqueous composition not containing sodium 4-phenylbutyrate, the increase in the preservation efficacy (logarithmic reduction value) by blending disodium ethylenediaminetetraacetate was limited to 0.4 (comparison of Comparative Examples 1 and 2). On the other hand, in the aqueous composition containing sodium 4-phenylbutyrate, the increase in the preservation efficacy (logarithmic reduction value) by blending disodium ethylenediaminetetraacetate was at least about 2 (comparison of Comparative Example 3 and Example 1). From the above, it was confirmed that the preservation efficacy was synergistically increased by combining sodium 4-phenylbutyrate and disodium ethylenediaminetetraacetate.
Claims
1. An aqueous composition comprising (A) 4-phenylbutyric acid or an ester thereof or a pharmacologically acceptable salt thereof, wherein the aqueous composition is contained in a container in which a part or the whole of a portion in contact with the aqueous composition is formed of a resin containing a polyolefin.
2. The aqueous composition according to claim 1, further comprising (B) a buffer.
3. The aqueous composition according to claim 1 or 2, further comprising (C) a chelating agent.
4. The aqueous composition according to claim 1 or 2, which has a pH of 6.0 or more and 9.0 or less.
5. An aqueous composition comprising (A) 4-phenylbutyric acid or an ester thereof or a pharmacologically acceptable salt thereof and (B) a chelating agent. 6 . The aqueous composition according to claim 5 , comprising 0.0002 to 1200 parts by mass of the component (B) based on 1 part by mass of the total content of the component (A).
7. The aqueous composition according to claim 5 or 6, further comprising (C) a buffer.
8. The aqueous composition according to claim 5 or 6, which has a pH of 5.0 or more and 9.0 or less.
Citation Information
Cited By
Pharmaceutical composition, preparation method therefor, and use thereof
WO2026130361A1
